Under this collaboration agreement,
The products and services to be developed under the collaboration will enable researchers and drug developers to use assays to assess responses to immunotherapies and select patients who are most likely to benefit from the therapies. This collaboration expands both companies' leadership in precision immuno-oncology and offers the potential for companion diagnostic collaborations with biopharmaceutical partners in the future.
"HalioDx is very excited to jointly develop with
"This collaboration with HalioDx adds another powerful tool to the nCounter immuno-oncology toolkit to support our customers' efforts in developing clinically validated predictive biomarkers for cancer immunotherapies. With the ability to process small tissue samples with minimal hands-on time,
For more information, please visit www.nanostring.com.
About HalioDx SAS
The Immune Response to
HalioDx designs and develops a unique range of immune scoring tests, whose first-in-class product is Immunoscore®. Considered a future diagnostic standard in Oncology, this biomarker has already demonstrated strong prognostic value in colorectal cancer.
HalioDx was founded in 2014 by the former management team of Ipsogen (leader in the molecular diagnosis of leukemia), and a pioneer in
integrative immunology and oncology, Dr.
HalioDx has an experienced team of 80 employees and compliant facilities to develop, manufacture, deliver and market in vitro diagnostic products and services in immuno-oncology.
For more information, please visit www.haliodx.com.
HalioDx and Immunoscore are registered trademarks.
Forward-Looking Statements -
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933
and Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. These forward-looking statements include statements regarding plans to jointly develop and commercialize advanced gene expression assays for assessing the response to immunotherapies on NanoString's nCounter system, the use of such assays to enable customers to more efficiently predict clinical outcomes for cancer immunotherapies, and the potential for companion diagnostic collaborations with biopharmaceutical partners in the future. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to: risks
associated with keeping pace with rapidly changing technology and customer requirements; risks regarding the company's ability to successfully develop and commercialize new products; risks that new market opportunities may not develop as quickly as expected; risks associated with competition in marketing and selling products; risks of increased regulatory requirements; as well as the other risks set forth in the company's filings with the
NanoString Mark Klausnerof Westwicke Partnersmark.firstname.lastname@example.org Phone: 443-213-1501 HalioDx ATCG PressMarie Puvieux ( France), Mob: +33 (0)6 10 54 36 72 Jean-Mehdi Grangeon(ROW), Mob: +33 (0)6 62 22 00 24 email@example.com
News Provided by Acquire Media